State Street Discloses Passive Stake in Replimune Group
Ticker: STT-PG · Form: SC 13G · Filed: Jan 25, 2024 · CIK: 93751
| Field | Detail |
|---|---|
| Company | State Street Corp (STT-PG) |
| Form Type | SC 13G |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**State Street just revealed a passive stake in Replimune, signaling institutional interest.**
AI Summary
State Street Corporation, a major financial institution, has filed an initial SC 13G form on January 25, 2024, disclosing its ownership of common stock in Replimune Group, Inc. as of December 31, 2023. This filing indicates that State Street holds a significant, passive stake in Replimune, a biological products company. For investors, this matters because it signals a large institutional investor's confidence in Replimune, potentially lending stability and credibility to the stock.
Why It Matters
This filing shows a major institutional investor, State Street Corporation, has taken a position in Replimune Group, Inc., which can be seen as a vote of confidence.
Risk Assessment
Risk Level: low — This is a routine disclosure of a passive investment by a large institution, indicating no immediate red flags or aggressive actions.
Analyst Insight
Smart investors should note this institutional endorsement and consider further research into Replimune Group, Inc.'s fundamentals and future prospects, as large passive stakes can provide a floor for the stock.
Key Numbers
- 76029N106 — CUSIP Number (Identifies Replimune Group, Inc. common stock)
- 04-2456637 — IRS Identification No. (Identifies State Street Corporation)
Key Players & Entities
- STATE STREET CORPORATION (company) — Reporting Person, a financial institution
- Replimune Group, Inc. (company) — Subject Company, a biological products company
- 0000093751-24-000185 (dollar_amount) — Accession Number for the filing
- 12/31/2023 (date) — Date of event requiring the filing
- 01/25/2024 (date) — Filing date
Forward-Looking Statements
- Other institutional investors may view State Street's stake as a positive signal, potentially leading to increased institutional interest in Replimune Group, Inc. (Replimune Group, Inc.) — medium confidence, target: Next 6-12 months
FAQ
What is the purpose of an SC 13G filing?
An SC 13G filing is used by institutional investors to report passive ownership of 5% or more of a company's outstanding shares, indicating they do not intend to influence or control the company's management or policies. This specific filing is an 'INITIAL FILING' for State Street Corporation regarding Replimune Group Inc.
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' is STATE STREET CORPORATION, a financial institution with IRS Identification No. 04-2456637, located at 1 Congress Street, Boston, MA.
Which company's stock is the subject of this filing?
The subject company is Replimune Group, Inc., a biological products company with CIK 0001737953, based at 500 Unicorn Park, Woburn, MA. The filing specifically concerns its 'COMMON STOCK'.
What was the 'Date of Event Which Requires Filing of This Statement'?
The 'DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT' was 12/31/2023, meaning State Street's ownership crossed the reporting threshold on or before this date.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under 'RULE 13D-1 (B)', which typically applies to institutional investors who acquire beneficial ownership of more than 5% of a class of equity securities in the ordinary course of business and without the purpose or effect of changing or influencing control of the issuer.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 25, 2024 regarding STATE STREET CORP (STT-PG).